Compared with placebo, treatment with extended-release phentermine-topiramate resulted in more weight loss and greater improvements in HbA1c in patients with type 2 diabetes, according to study results published in Diabetes Care.
To determine the impact of phentermine-topiramate extended-release (ER), in addition to lifestyle modification, on weight loss and glycemic control in overweight or obese adults with type 2 diabetes, researchers conducted two randomized, double blind, placebo-controlled trials
In one 56-week trial (OB-202/DM-230), the researchers randomly assigned 130 participants to once-daily placebo or phentermine-topiramate ER 15 mg/92 mg. Change in HbA1c served as the primary endpoint.
They also included results from a post-hoc analysis of the type 2 diabetes cohort (n=388) of the CONQUER study.
In OB-202/DM-230, weight change was significantly greater for the phentermine-topiramate ER group vs. the placebo group from intent-to-treat sample to last observation carried forward at week 56 (–9.4% vs. –2.7%; P<.0001). Change in HbA1c was also significantly greater for the phentermine-topiramate ER group vs. placebo (–1.6% vs. –1.2%; P=.0381).
HbA1c targets were achieved by more participants taking phentermine-topiramate ER with less need for medication in both OB-202/DM-230 and CONQUER, the researchers reported.
In light of their results, the researchers concluded that phentermine-topiramate, in addition to lifestyle modification, offers a viable treatment option for obese or overweight patients with type 2 diabetes.
Treatment algorithms suggest weight loss is beneficial in the management of type 2 diabetes. Researchers sought to see whether phentermine-topiramate extended-release could potentially improve weight loss and improve glycemic control in overweight and obese patients with type 2 diabetes using double blind, randomized, placebo-controlled trials.